161 related articles for article (PubMed ID: 12646859)
1. Hypoxia-mediated tumour targeting.
Binley K; Askham Z; Martin L; Spearman H; Day D; Kingsman S; Naylor S
Gene Ther; 2003 Apr; 10(7):540-9. PubMed ID: 12646859
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia- and radiation-activated Cre/loxP 'molecular switch' vectors for gene therapy of cancer.
Greco O; Joiner MC; Doleh A; Powell AD; Hillman GG; Scott SD
Gene Ther; 2006 Feb; 13(3):206-15. PubMed ID: 16307003
[TBL] [Abstract][Full Text] [Related]
3. GCV modulates the antitumoural efficacy of a replicative adenovirus expressing the Tat8-TK as a late gene in a pancreatic tumour model.
Cascante A; Abate-Daga D; Garcia-Rodríguez L; González JR; Alemany R; Fillat C
Gene Ther; 2007 Oct; 14(20):1471-80. PubMed ID: 17713568
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional targeting of RGD fiber-mutant adenovirus vectors can improve the safety of suicide gene therapy for murine melanoma.
Okada Y; Okada N; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T
Cancer Gene Ther; 2005 Jul; 12(7):608-16. PubMed ID: 15746944
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase.
Mizuguchi H; Hayakawa T
Cancer Gene Ther; 2002 Mar; 9(3):236-42. PubMed ID: 11896439
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy.
Lanuti M; Gao GP; Force SD; Chang MY; El Kouri C; Amin KM; Hughes JV; Wilson JM; Kaiser LR; Albelda SM
Hum Gene Ther; 1999 Feb; 10(3):463-75. PubMed ID: 10048398
[TBL] [Abstract][Full Text] [Related]
7. Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity.
Zhang R; Straus FH; DeGroot LJ
Thyroid; 2001 Feb; 11(2):115-23. PubMed ID: 11288980
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
9. Genetically modified macrophages expressing hypoxia regulated cytochrome P450 and P450 reductase for the treatment of cancer.
Kan O; Day D; Iqball S; Burke F; Grimshaw MJ; Naylor S; Binley K
Int J Mol Med; 2011 Feb; 27(2):173-80. PubMed ID: 21165551
[TBL] [Abstract][Full Text] [Related]
10. Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo.
Nishihara E; Nagayama Y; Mawatari F; Tanaka K; Namba H; Niwa M; Yamashita S
Endocrinology; 1997 Nov; 138(11):4577-83. PubMed ID: 9348181
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo.
Harvey TJ; Hennig IM; Shnyder SD; Cooper PA; Ingram N; Hall GD; Selby PJ; Chester JD
Cancer Gene Ther; 2011 Nov; 18(11):773-84. PubMed ID: 21836632
[TBL] [Abstract][Full Text] [Related]
12. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
Chen L; Waxman DJ; Chen D; Kufe DW
Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
[TBL] [Abstract][Full Text] [Related]
13. Comparison of long-term survival of cytomegalovirus promotre versus Rous Sarcoma virus promoter-driven thymidine kinase gene therapy in nude mice bearing human ovarian cancer.
Tong X; Engehausen DG; Freund CT; Agoulnik I; Oehler MK; Kim TE; Hasenburg A; Guo Z; Contant CF; Woo SL; Kieback DG
Hybridoma; 1999 Feb; 18(1):93-7. PubMed ID: 10211795
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells.
Koshikawa N; Takenaga K; Tagawa M; Sakiyama S
Cancer Res; 2000 Jun; 60(11):2936-41. PubMed ID: 10850440
[TBL] [Abstract][Full Text] [Related]
15. Reduced growth in response to ganciclovir treatment of subcutaneous xenografts expressing HSV-tk in the vascular compartment.
Mavria G; Porter CD
Gene Ther; 2001 Jun; 8(12):913-20. PubMed ID: 11426331
[TBL] [Abstract][Full Text] [Related]
16. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters.
Majumdar AS; Hughes DE; Lichtsteiner SP; Wang Z; Lebkowski JS; Vasserot AP
Gene Ther; 2001 Apr; 8(7):568-78. PubMed ID: 11319624
[TBL] [Abstract][Full Text] [Related]
17. Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ ganciclovir therapy of hepatocellular carcinoma: the woodchuck animal model.
Bilbao R; Gérolami R; Bralet MP; Qian C; Tran PL; Tennant B; Prieto J; Bréchot C
Cancer Gene Ther; 2000 May; 7(5):657-62. PubMed ID: 10830712
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene.
Esandi MC; van Someren GD; Vincent AJ; van Bekkum DW; Valerio D; Bout A; Noteboom JL
Gene Ther; 1997 Apr; 4(4):280-7. PubMed ID: 9176512
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM
Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705
[TBL] [Abstract][Full Text] [Related]
20. Cell-specific viral gene therapy of a Hurthle cell tumor.
Zhang R; Straus FH; DeGroot LJ
J Clin Endocrinol Metab; 2002 Mar; 87(3):1407-14. PubMed ID: 11889217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
